Clinical Trial

Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery

Recruiting
View on ClinicalTrials.gov →
Summary
This prospective, randomized controlled study aims to evaluate the efficacy and safety of electroacupuncture combined with 5-HT3 receptor inhibitor for preventing postoperative nausea and vomiting (PONV) in high-risk patients undergoing thoracoscopic lung cancer surgery. The primary outcome is the incidence of PONV within 24 hours after surgery.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-31.
Trial Details
NCT Number NCT07515027
Lead Sponsor Shanghai Chest Hospital
Conditions PONV
Enrollment 204 participants
Start Date 2026-04-07
Primary Completion 2026-11-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-13